Clinical Trials Directory

Trials / Completed

CompletedNCT00004387

Phase II Double Blind Controlled Trial of Nigral Grafting in Patients With Parkinson's Disease

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
34 (planned)
Sponsor
National Center for Research Resources (NCRR) · NIH
Sex
All
Age
35 Years – 75 Years
Healthy volunteers
Not accepted

Summary

OBJECTIVES: I. Determine the effectiveness of fetal nigral transplantation in patients with Parkinson's disease.

Detailed description

PROTOCOL OUTLINE: This is a placebo controlled, randomized, double blind study. Patients are randomly assigned to 1 of 3 treatment groups. All patients receive 2 separate operations in which the substantia nigra from either 4 fetuses (Group A) or 1 fetus (Group C) is implanted into the striatum of each side. Group B patients receive 2 separate placebo operations without fetal transplantation. The second surgical procedure begins approximately 1 week after the first operation. After 2 years, treatments are compared. If transplant is shown to benefit Parkinson's disease, then patients who received placebo operation will be offered transplant surgery in the final year of the study.

Conditions

Interventions

TypeNameDescription
PROCEDUREfetal nigral transplantation

Timeline

Start date
1996-01-01
First posted
1999-10-19
Last updated
2005-06-24

Source: ClinicalTrials.gov record NCT00004387. Inclusion in this directory is not an endorsement.